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background: Polycystic ovary syndrome (PCOS) is a common condition affecting8%of women. The objective of the present study was
to quantify separately the risk of endometrial cancer, ovarian cancer and breast cancer inwomenwith PCOS comparedwith non-PCOS controls,
and quantify separately the risk to women of all ages as well as the risk to premenopausal women.
methods:Weconducted a systematic review andmeta-analysis of observational studies. Studies were eligible for inclusion if they compared
women with PCOS to non-PCOS groups for fatal or non-fatal gynaecological cancers. Studies listed in MEDLINE and EMBASE published up to 7
October2013 in any languagewere identiﬁed, and relevantpaperswerealso searchedbyhand.Relevant data (forexample, studydesign, sourceof
control data, diagnostic criteria) were extracted and tabulated.
results: From698references,11 studies (5ofendometrial cancerand3eachof ovarianandbreast cancer)met the inclusioncriteria for themeta-
analysis (919 women with PCOS and 72054 non-PCOS controls). Using the Mantel–Haenszel method, with ﬁxed or random effects model as
appropriate, women with PCOS were at a signiﬁcantly increased risk of endometrial cancer (odds ratio (OR), 2.79; 95% conﬁdence interval (CI),
1.31–5.95, P, 0.008), but the risk of ovarian and breast cancers was not signiﬁcantly increased (OR, 1.41; 95% CI, 0.93–2.15, P, 0.11 and OR,
0.95; 95%CI, 0.64–1.39, P, 0.78, respectively). Howeverwhen studieswhich includedwomen agedover 54 yearswere excluded from theanalysis,
the risk forwomenwith PCOS increased further for endometrial cancer (OR, 4.05; 95%CI, 2.42–6.76, P, 0.00001), became signiﬁcantly increased
forovarian cancer (OR, 2.52; 95%CI, 1.08–5.89, P, 0.03), but remainednon-signiﬁcant forbreast cancer (OR,0.78; 95%CI, 0.46–1.32, P, 0.35).
conclusions: This is the ﬁrst meta-analysis to examine gynaecological cancers in women with PCOS younger than 54 years of age compared
with controls of similar age.Current data suggest thatwomenofall ageswithPCOSareat an increased riskof endometrial cancerbut the riskofovarian
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and breast cancer was not signiﬁcantly increased overall. These results highlight the potential risk of gynaecological cancermorbidities associatedwith
PCOS.However, the availableevidence is far fromrobust andvariation indiagnostic criteria forPCOS, associated risk factors (particularlyobesity), and
selection bias in the studies may have resulted in an exaggeration of the increased risk. Furthermore, women who have PCOS should also be made
aware that any increased risk forendometrial cancermust be judged in the context of its relatively low incidence in the general population.A largewell-
controlled prospective study is required in order to gain a more accurate estimate of the risk of gynaecological cancers in women with PCOS.
prospero crd registration number: CRD42012003500.
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Introduction
Polycystic ovary syndrome (PCOS) is a very commonhormonal disorder
affecting5–8%ofwomenof reproductiveage (Azziz et al., 2004). It has
an insidious onset with a clinical spectrum which includes the classical
triad of PCOS: hyperandrogenism,menstrual abnormalities and polycys-
tic ovaries (ESHRE/ASRM, 2004; Azziz et al., 2006; Broekmans et al.,
2006).Althoughoriginally considereda gynaecologic andendocrine con-
dition, PCOS is now recognized as a multi-system disorder (Solomon,
1999). The discovery of insulin resistance in the 1980s was followed by
studies showing an increase of type II and gestational diabetes, and via
metabolic syndrome to increased morbidity from coronary heart
disease and stroke (Dunaif, 1997; Broekmans et al., 2006; Diamanti-
Kandarakis et al., 2007; RCOG, 2007; Shroff et al., 2007).
Concerns thatwomenwith PCOSmight be at increased risk of cancer
date back to the 1940s (Legro, 2007) but this risk is still frequently over-
looked by the doctors who care for these women. Any association with
malignant disease would be highly important from a public health per-
spective in view of the high prevalence of PCOS. In practice, this lack
of recognition means that women are not advised of this risk, preventa-
tive treatment is not offered even to those patients at highest risk and
diagnosis of pre-malignant or malignant disease is delayed. In part this
lack of recognition can be explained by the relative lack of studies in
this ﬁeld compared with those investigating cardiovascular morbidity in
women with PCOS (Hardiman et al., 2003).
The ﬁrst reports of an association between PCOS and cancer related
to endometrial disease (Speert, 1949; Dockerty et al., 1951; Dockerty
and Jackson, 1957; Jafari et al., 1978;Gallup andStock, 1984;Kurabayashi
et al., 2003). More recently the possibility of an increased risk of ovarian
and breast malignancy has been suggested (Gammon and Thompson,
1991; Schildkraut et al., 1996). At a cellular level there are numerous po-
tential mechanisms which could promote neoplastic disease in women
with PCOS, including the prolonged anovulatory state and associated
hyperandrogenism with unopposed estrogen action (Key and Pike,
1988; Genazzani et al., 2001). These could increase the risk of cancer
through the effect of these hormones on various tissue and organs
(Wild et al., 2000; Hardiman et al., 2003). PCOS emerged as a risk
factor for endometrial cancer many years ago from a small number of
case reports. We previously highlighted the lack of robust evidence to
support an association with endometrial cancer (Hardiman et al.,
2003) but a recent meta-analysis (Haoula et al., 2012) of pooled data
from ﬁve comparative studies concluded that women with PCOS were
about three times more likely to develop endometrial cancer than
other women. Similarly, a population-based case–control study
(Schildkraut et al., 1996) raised the possibility of risk of ovarian cancer
in women with PCOS, although other studies have not supported this
contention (Coulam et al., 1983; Pierpoint et al., 1998). Inconsistent
ﬁndings also exist regarding the prevalence of breast cancer in women
with PCOS (Anderson et al., 1997; Pierpoint et al., 1998).
The cancers discussed in this paper are all highly age-related. The peak
incidence for endometrial cancer is90 per 100 000women (0.09%) at
age 70 years.One in eightwomen develop breast cancer, and this occurs
post-menopausally in 80% of cases. Similarly, most cases of ovarian
cancer occur post-menopausally (Cancer Research UK, 2013). The
last systematic review of endometrial, ovarian and breast cancer risk in
PCOSwas published in 2009 (Chittenden et al., 2009). The authors iden-
tiﬁed eight studies to show that women with PCOS were more likely to
develop endometrial cancer (odds ratio (OR) 2.70, 95% conﬁdence
interval (CI) 1.00–7.29) and ovarian cancer (OR 2.52, 95% CI 1.08–
5.89) but not breast cancer (OR 0.88, 95% CI 0.44–1.77). However,
their analysis of ovarian cancer included only one study (Schildkraut
et al., 1996) and therefore could not provide a meta-analysis of studies
of ovarian cancer. No assessment was made of publication bias or the
quality of included studies. Chittenden et al. (2009) also included three
studies that were of polycystic ovaries rather than PCOS (Gammon
and Thompson, 1991; Baron et al., 2001; Pillay et al., 2006), making
the ﬁndings less generalizable to women with a diagnosis of PCOS.
Most importantly, the review by Chittenden et al. (2009) combined
data from women with PCOS of a very wide age range, and the studies
included deﬁned PCOS in a variety of ways. Since then Haoula et al.
(2012) published a systematic reviewwhich consideredonlyendometrial
cancer and added onemore study to those analysed by Chittenden et al.
(2009). In the light of the Cochrane Collaboration recommendation
to update systematic reviews at 2-yearly intervals, we designed the
present study to investigate the strength of the association between
all three cancers and PCOS (Reeves et al., 2011). In a further develop-
ment on previous reviews, we investigated the view - which has been
expressed but is unproven-that the strength of association of cancer in
womenwithPCOS is inﬂuencedbyage(Pillayetal., 2006).This is therefore
the ﬁrst report of a separate subgroup analysis of the effect of age, ex-
cluding studies that includedwomenover theageof54years,whoarepre-
sumed tobepost-menopausal (5of the11 studies).A furtherdistinctionof
this meta-analysis study over previous meta-analyses on this topic is the
use of Newcastle Ottawa Quality Assessment Scale (NOS) criteria to
assess the methodological quality of included studies.
Methods
Data sources and study selection
The guidelines issued by Stroup et al. (2000) were followed in the implemen-
tationof thismeta-analysis.Qualiﬁed librarians advisedon the search strategy
and assisted where papers were difﬁcult to access. The study protocol is
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available on theCentre forReviewsandDissemination (CRD)website (regis-
tration number CRD42012003500).
Inclusion and exclusion criteria
Studies that compared cancer events in women with PCOS to non-PCOS
controls were eligible for inclusion provided that:
(i) The study reported the actual number of women from each group who
experienced the event and the number who did not experience the
event;
(ii) The studies reported other relevant data, e.g. the number of women in
each group;
Papers with titles or abstracts that indicated that they were not relevant, for
example, animal studies, reviews, or single case studies, were excluded.
Papers not published in English were reviewed.
The search replicated that by Chittenden et al. (2009). All published
studies that assessed theprevalenceof both fatal andnon-fatal gynaecological
cancers were included in the search. The cancer sites included were endo-
metrial, ovarian, and breast cancer. Studies listed in MEDLINE published
up to 7 October 2013, and EMBASE from 1980 to 7 October 2013, were
identiﬁed. Any comparative design was eligible for inclusion (prospective
or retrospective, case–control or cohort studies), including studies that
used normative population data as a comparison arm of the research
design. The following keyword search terms were entered simultaneously:
‘(polycystic ovar* OR polycystic ovary syndrome OR PCOS OR PCO OR
Stein-Leventhal) and (breast cancer OR breast carcinoma OR endometrial
cancerORendometrial carcinomaORovarian cancerORovarian carcinoma
OR leiomyosarcomaORuterine sarcomaORvulval cancerORvulvar carcin-
omaORcervical cancerORcervical carcinomaORvaginal cancerORvaginal
carcinoma OR cervical intraepithelial neoplasia OR CIN)’. A MEDLINE
search from 1946 to Week 1 October 2013 retrieved 269 papers. An
EMBASE search from 1980 toWeek 41 (Week 1 October) 2013 produced
429 results. A hand search of the resulting papers produced no further rele-
vant papers. Authors were contacted where additional information was
needed. For example, Iatrakis et al. (2006) stated the PCOS diagnosis was
conﬁrmed, but did not state which diagnostic criteria was used (in this
case, no further data could be obtained).
Data extraction
Datawere collected and coded based on clinical relevance, for example BMI
data were collected because of the clinical relevance of BMI to the develop-
ment of cancer (Renehan et al., 2008). The primary analyses estimated the
ORs for cancer in women with PCOS. Sub-analyses were conducted to
test for any effect of age and type of PCOS diagnosis.
Information was extracted from each study regarding: (i) characteristics of
the participants (age, BMI, ethnicity and method of diagnosis); (ii) the com-
parison (PCOS compared with controls); (iii) the outcome(s) measured
(fatal or non-fatal endometrial, ovarian, or breast cancer, as separate end-
points); and (iv) the study design (case–control or cohort). Additional data
were extracted in order to assess the methodological quality of each study.
The quality assessment criteria were: (i) whether the PCOS diagnosis was
sound; (ii) whether selection bias could be ruled out; (iii) whether the
control group was selected from hospital or the community; (iv) whether
the control group was assessed for PCOS status; (v) whether the PCOS
and control group were comparable in terms of age and BMI; (vi) ascertain-
ment of diagnosis; (vii) whether the ascertainment of diagnosiswas similar for
PCOS and control group; (viii) whether the response rate was similar in the
PCOS and control group.
Each article was assessed by authors J.A.B. and P.J.H., and articles that
ﬁtted the main criteria (assessing gynaecological cancer in women with
PCOS) were accessed. Methodological quality was assessed by J.A.B. and
M.M.A. based on the criteria of the NOS for case–control studies (Wells
et al., 2011). The Cochrane Non-Randomized Studies Methods Working
Group considers the NOS an acceptable tool for assessment of non-
randomized studies (Reeves et al., 2011). Inter-rater agreement of NOS
scoringwasassessedusingCohen’sKappa.AKappaof 0.41–0.60 is generally
considered as demonstrating ‘moderate agreement’ and 0.61–0.80 is ‘sub-
stantial agreement’ (Landis and Koch, 1977); The NOS scores of J.A.B.
and M.M.A. were in substantial agreement, as shown by the Cohen’s
Kappa of 0.750 (P, 0.00002). Discrepancies were examined and discussed
before a ﬁnal score was agreed upon and assigned.
The raw numbers of events in each study in each of the PCOS and
non-PCOS samples from each study were identiﬁed and calculated as a
common unit, the OR. The OR is the ratio of the odds of the outcomes in
each group. The Mantel–Haenszel method was used, with a random
effects model in most cases, to generate an OR for all included studies com-
bined. Results were considered statistically signiﬁcant where the probability
value was below the 0.05 threshold. Review Manager statistical software,
version 5.2, was used to analyse data.
The outcome measure was a diagnosis of cancer. With the exception of
some of the women in one study (Anderson et al., 1997), the women in
the included studieswere alive at the timeof the studymeasurements; there-
fore it could be said that the outcome was mainly non-fatal cancer.
Results
Eligible articles
Figure 1 summarizes the search strategy used to identify appropriate
studies. Of the 698 initially retrieved, after duplicates were removed
the titles and abstracts of 212 records were assessed. A total of 31 full
texts were further assessed, including reference sections, and 20 were
excluded for various reasons (for example, polycystic ovaries rather
than PCOS was identiﬁed). Finally, 11 papers met all of the inclusion
and exclusion criteria.
The 11 studies that met the inclusion criteria for the meta-analysis
(919 women with PCOS and 72 054 non-PCOS controls) are listed in
Table I. Most of the studies were: of case–control design, diagnosed
cancer histologically, diagnosed PCOS by self-report, did not control
for BMI, and consisted mainly of Caucasian patients. Five of the 11
studies included groups of women over the age of 54 years. Because
menopause may be clinically relevant to the risk of gynaecological
cancers, sub-analyses based on age were carried out.
Methodological quality
Regarding the quality of the studies, in general the NOS scores were
moderate. Table II shows that the scores ranged from two to six.
Data analysis
Heterogeneity was assessed using I2 and x2 statistics. I2 values of 30% or
above were considered likely to indicate moderate heterogeneity and I2
value .50% indicative of substantial heterogeneity. x2 P-values ,0.10
were considered to represent signiﬁcant heterogeneity. Therefore
studies showing tolerable levels of heterogeneity (I2 values ,30% and
x2 P-values .0.10) were analysed using a ﬁxed effects model, and
studies showing any greater degree of heterogeneity were analysed
using a random effects model.
Figures 2a and 3a show that the ORs for all ﬁve of the studies of
endometrial cancer and all three of the studies of ovarian cancer
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independently showed an increased risk of cancer events associated with
PCOS. Figure 4a shows that two of the three studies of breast cancer
reported a reduction in risk for women with PCOS. Figure 2b shows that
the effect size for endometrial cancer increased when the age of the
sample was taken into account. In the only study which reported ovarian
cancer in younger women, the risk was signiﬁcantly higher in women
with PCOS (Fig. 3b) but self-evidently it was not possible to perform a
meta-analysis, because there was only one study. The risk for breast
cancer (Fig. 4b) did not show any signiﬁcant difference between PCOS
and controls, either overall or in the subgroup analysis of younger women.
Table III shows the results of themeta-analysis of themain groups and
subgroups. Using the Mantel–Haenszel method, with ﬁxed or random
effects model as appropriate, women with PCOS were at a signiﬁcantly
increased risk of endometrial cancer (P, 0.008), but not for ovarian
cancer (P, 0.11), nor breast cancer (,0.78). When women aged
over 54 years old were excluded from the analysis, the risk for women
with PCOS increased further for endometrial cancer (P, 0.00001),
became signiﬁcantly increased for ovarian cancer (P, 0.03) (although
this ﬁnding is on data from a single study, so meta-analysis was not pos-
sible) and remained relatively unchanged for breast cancer (P, 0.35).
Publication bias
To assess publication bias, funnel plots were created (Figs 5–7).
The funnel plot of the ﬁndings for endometrial cancer (Fig. 5) is asym-
metrical, mainly due to two studies with small sample sizes (Niwa et al.,
2000; Iatrakis et al., 2006) (see the lower right of the plot). Becauseof this
asymmetry, publication bias cannot be ruled out. The funnel plots for
ovarian and breast cancer studies (Figs 6 and 7) show less asymmetry,
though because the number of studies in each plot (N ¼ 3) is small, it
is difﬁcult to draw ﬁrm conclusions regarding publication bias.
Discussion
This is the ﬁrst systematic review of gynaecological and breast malignan-
cies inwomenwith PCOS tobepublished since 2009 and the ﬁrst ever to
separately analyse the risk in premenopausal and post-menopausal
women (categorized as women less than and over 54 years of age,
respectively)with this syndrome.Ouranalysis identiﬁed twostudiespub-
lished during the 2 years since the lastmeta-analysis (Haoula et al., 2012).
The clinical utility of the two previous meta-analyses (Chittenden et al.,
2009; Haoula et al., 2012) is uncertain because in both cases the analyses
included patients on the basis of polycystic ovary morphology (PCOM)
either on ultrasound or histopathology as well as patients with PCOS:
Chittenden et al. (2009) had included three studies of PCOM
(Gammon and Thompson, 1991; Baron et al., 2001; Pillay et al., 2006)
and Haoula et al. (2012) included one (Pillay et al., 2006). Around 20%
of European women have polycystic ovaries (the prevalence is even
higher in some other populations) but approximately two-thirds of
these women do not have PCOS (Polson et al., 1988; Clayton et al.,
1992). The morbidity associated with PCOS and polycystic ovaries
cannot be assumed to be the same and therefore wemade the decision
not to include studies of women selected on the basis of their ovarian
morphology alone. Consequently our results should be more relevant
to clinical practice as they reﬂect the risk amongst our patients rather
than asymptomatic women in the general population. However, even
Figure 1 Flow diagram of the literature search for studies of fatal and
non-fatal endometrial, ovarian, and breast cancer.
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Table I Characteristics of the 11 studies included in themeta-analysis to assess the risk of endometrial, ovarian and breast cancer in womenwith polycystic ovary
syndrome (PCOS).
Study name Cancer
site
Study design Diagnostic criteria Ca Diagnostic criteria PCOS Age in years
[age category]
Controlled for BMI Ethnic group
Escobedo
et al. (1991)
Endometrium Case–control
(Dec 1980–1982)
Histologically conﬁrmed Ca
infertility patients.
Physician diagnosed
Self-report to trained
interviewers. Criteria not
stated.
All 20–54
(matched age
group)
[,54]
No EC cases 92% white, 6% Black; 2%
other. Ethnicity of Controls not
stated, but selected from same
regions as cases
Schildkraut
et al. (1996)
Ovary Case–control
(Dec 1980– Dec
1982)
Histologically conﬁrmed epithelial
Ca.
Physician diagnosed
Self-report Stein-Leventhal
syndrome or pco from
interview. Criteria not stated.
All 20–54
[,54]
No Not stated, but all fromWestern
USA. Controls chosen by random
digit phoning
Anderson
et al. (1997)
Breast Cohort (Jan
1986–Dec 1992)
ICD codes 174.0–174.9.
Included fatalities.
Self-report. Stein-Leventhal
syndrome.
All aged 55–69
[.54]
No signiﬁcant
difference
Mail survey, Iowa, USA
Talamini et al.
(1997)
Breast Case–control
(1991–1994)
Histologically conﬁrmed Ca.
Diagnosed by past history
Self-report. Stein-Leventhal
syndrome.
All 20–74
[.54]
Data not shown, but
BMI had little impact on
ORs
From across Italy.
Niwa et al.
(2000)
Endometrium Case–control
(1988–1997)
Histologically conﬁrmed primary
carcinoma.
Physician diagnosed
Clinical data. Diagnosis based
on Goldzieher (1981).
All , 40
[,54]
No 100% Japanese
Iatrakis et al.
(2006)
Endometrium Case–control
(Dec 1992–2004)
Histologically conﬁrmed
carcinoma. Physician diagnosed
Self-report. Criteria not stated. All 43–48
[,54]
No Not stated, but study is Greek.
Olsen et al.
(2008)
Ovary Case–control New diagnosis of invasive
epithelial Ca (n ¼ 1276) or
borderline malignant tumour
(n ¼ 315).
Self-report Criteria not stated. Ca 18–79
Controls age
matched+5
years
[.54]
No, but no signiﬁcant
difference
Not stated except from Australia.
Controls from electoral roll.
Zucchetto
et al. (2009)
Endometrium Case–control
(1992–2006)
Histologically conﬁrmed Ca ,1
year; noearlier diagnosis of cancer
Self-report to trained
interviewers. Criteria not
stated.
All 18–79
[.54]
No From Pordenone, Milan and Naples,
Italy.
Fearnley et al.
(2010)
Endometrium Case–control
(2003–2007)
Histologically conﬁrmed
carcinoma newly diagnosed.
Self-report & criteria not stated. Ca 18–50
Control ,50
[,54]
No Not stated except from Australia.
Controls from electoral roll.
Ghasemi et al.
(2012)
Breast Case–control
(no dates)
Histologically conﬁrmed primary
Ca
Rotterdam, with interview,
conﬁrmed by USS.
All 30–51
age matched
[,54]
No, but no signiﬁcant
difference
Not stated. Study is Iranian.
Bodmer et al.
(2011)
Ovary Case–control
(GPRD,
1995–2009)
Ca diagnosis with evidence of
Ca-related treatment.
Not stated, but used a diagnosis
from GPRD
All 61.2 (SD 13.1)
Age matched
[.54]
80% BMI matched 92% white
Ca, cancer; Rotterdam, Rotterdam diagnostic criteria; GPRD, General Practice Research Database; ICD, International Statistical Classiﬁcation of Diseases; pco, polycystic ovaries; USS, ultrasound scan; OR, odds ratio; EC, endometrial cancer.
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Table II Evaluation of the methodological quality of the 11 studies included in the meta-analysis using an adapted version of the Newcastle-Ottawa Quality
Assessment Scale (NOS).
Study PCOS case
deﬁnition
adequate
Representativeness of
PCOS cases
Selection of
non- PCOS
controls
Deﬁnition of
non- PCOS
controls
Comparability of
both groups
Ascertainment
of diagnosis
Same
ascertainment
method for both
groups
Non-response
rate
NOS
score
Escobedo
et al. (1991)
X X X X X * X * 2
Schildkraut
et al. (1996)
X * * * X * * * 6
Anderson
et al. (1997)
X X * * X * * * 5
Talamini et al.
(1997)
X X * * X * * * 5
Niwa et al.
(2000)
X X * * X * * X 4
Iatrakis et al.
(2006)
X X X * X * * X 3
Olsen et al.
(2008)
X * * * X * * X 5
Zucchetto
et al. (2009)
X X * * * * * * 6
Fearnley et al.
(2010)
X * * * X * * X 5
Ghasemi
et al. (2012)
* X X * X * * X 4
Bodmer et al.
(2011)
X * * * X X * * 5
Note that the evaluation is in regards to being a sound study of PCOS rather than a sound study of cancer.
Note: ‘*’ indicates NOS quality assessment star awarded; ‘X’ indicates that no star was awarded.
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after excluding studies based on ovarian morphology, it is possible that
variations in diagnostic criteria for PCOScould have introduced selection
bias into our analysis; only one study of the 11 included used the Rotter-
dam criteria (Ghasemi et al., 2012), another two used non-standard cri-
teria (Niwa et al., 2000; Bodmer et al., 2011) and in the remaining eight
the syndrome was self-reported so that the criteria were unknown.
Concerns regarding the reliability of PCOSdiagnosis are further raised
by the prevalence of the syndrome in some of the included studies. For
example, Iatrakis et al. (2006) found three cases of PCOS in 81 women
with endometrial cancer, a prevalence for the syndrome of only 3.7%,
but of greater concern is that the prevalence was 0% in the control
group. These ﬁgures are difﬁcult to reconcile with those found in the
Figure2 (a andb)Upper forest plot: endometrial cancer inwomenwith polycystic ovary syndrome (PCOS) comparedwith controls. Lower forest plot:
endometrial cancer in PCOS compared with controls in women under 54 years old.
Figure3 (a andb)Upper forest plot: ovarian cancer inwomenwithPCOScomparedwith controls. Lower forest plot: ovariancancer inPCOScompared
with controls in women under 54 years old.
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general population and cast doubt on the reliability of the data in that
study.
Subject to these important caveats, the results of this meta-analysis
suggest that women with PCOS of all ages are at an increased risk of
endometrial cancer, but the riskof ovarian and breast cancerwas not sig-
niﬁcantly increased overall.
Our analysis of women aged,54 years (in practical terms, premeno-
pausal subjects) conﬁrmed previous suggestions that the risk of endo-
metrial cancer may be even higher in this subgroup of women with
PCOS. It is of interest that in the three studies which reported ovarian
cancer, the increased risk in women with PCOS was not signiﬁcant,
but the OR was higher and signiﬁcant in the single study of women
aged,54 years. The risk for breast cancer was not signiﬁcantly different
in PCOS compared to the control women overall, or in the subgroup
analysis of the two studies of younger women with breast cancer. This
ﬁnding for endometrial disease is consistent with the observation that
post-menopausal women tend to have type II endometrial cancer,
which has not been shown to be associated with PCOS, unlike type I
(Gadducci et al., 2005).
Overall our results are consistent with previous reviews published on
cancer in PCOS (Hardiman et al., 2003; Broekmans et al., 2006) although
the addition of further studies to this meta-analysis has added statistical
power. A previous meta-analysis (Chittenden et al., 2009) of eight
studies found that women with PCOS were more at risk of endometrial
Figure4 (a andb) Upper forest plot: breast cancer in womenwith PCOS comparedwith controls. Lower forest plot: breast cancer in PCOS compared
with controls in women under 54 years old.
.............................................................................................................................................................................................
Table III Findings of the present meta-analysis of 11 studies, with subgroup analysis based on age of the women (over or
under age 54 years).
Disease site Studies included in analysis Number of
studies
Odds ratio
(95% conﬁdence
interval)
Z x2 I2
Endometrial cancer All endometrial cancer studies 5 2.79 (1.31–5.95) 2.65 (P, 0.008) 11.33 (P, 0.02) 65%
Excluding samples that included
women over age 54 years
(Zucchetto et al., 2009)
4 4.05 (2.42–6.76) 5.34 (P, 0.00001) 0.65 (P, 0.88) 0%
Ovarian cancer All ovarian cancer studies 3 1.41 (0.93–2.15) 1.62 (P, 0.11) 2.39 (P, 0.30) 16%
Excluding samples that included
women over age 54 years
(Olsen et al., 2008; Bodmer et al., 2011)
1 2.52 (1.08–5.89) 2.14 (P, 0.03) n/a n/a
Breast cancer All breast cancer studies 3 0.95 (0.64–1.39) 0.27 (P, 0.78) 1.42 (P, 0.06) 0%
Excluding samples of women over
age 54 years (Anderson et al., 1997)
2 0.78 (0.46–1.32) 0.93 (P, 0.35) 0.26 (P, 0.61) 0%
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cancer and ovarian cancer, but not breast cancer. However, that paper
only includedone studyof ovarian cancerand thuswasunable to conduct
ameta-analysis for this disease. Themeta-analysis of endometrial cancer
in PCOS (Haoula et al., 2012) added one study (Fearnley et al., 2010) to
those in Chittenden et al. (2009), but did not take into consideration
another study (Zucchetto et al., 2009), and like Chittenden et al.
(2009) included one study of polycystic ovaries (Pillay et al., 2006). The
present meta-analysis has been able to include two new studies
(Ghasemi et al., 2012; Bodmer et al, 2011). The ﬁnding with respect to
endometrial cancer is also in accord with two studies which did not
meet the inclusion criteria for our meta-analysis. In a case series of 176
women with endometrial cancer (Dahlgren et al., 1991), the prevalence
of hirsutism (but not oligomenorrhoea) was signiﬁcantly higher in the
cases than in the general population; the study was excluded as it did
not include any diagnosis of PCOS. In the study by Lunde and Tanbo
(2007) of 149 women who underwent ovarian wedge resection for
PCOS, the standardized incidence ratio for endometrial cancer was
4.4 but this was not statistically signiﬁcant; this study was excluded
because it did not report the numbers of cancer cases and non-cases
in the control group.
As with studies of cardiovascular risk in women with PCOS, assess-
ment of cancer risk is complicated by the possible confounding effects
of obesity. High BMI is a recognized risk factor for both endometrial
and breast cancer; there is also some evidence of an association with
ovarian cancer, although this increased risk may not apply to invasive
serous cancers (Webb, 2013). It is therefore possible that our ﬁnding
of increased risk for endometrial malignancy might result, at least in
part, from the increased prevalence of obesity in women with PCOS.
In support of this hypothesis, here we found that the risk of ovarian
cancer was slightly decreased in studies where BMI was similar in the
PCOS and non-PCOS groups. Diabetes is another possible confounding
factor in our analysis as this is also associated with an increased risk of
endometrial cancer, possibly secondary to hyperinsulinemia, hypergly-
caemia and inﬂammation (Giovannucci, 2007). PCOS shares these risk
factors (obesity, diabetes, inﬂammation, metabolic syndrome, age) and
it is unclear whether the increased risk of endometrial cancer is due to
individual risk factors (diabetes, obesity) or whether PCOS itself, with
its speciﬁc metabolic features (such as hyperinsulinism, hyperglycaemia,
insulin resistance, hyperandrogenism), increases the risk of cancer. It is
possible that the observed association between PCOS and endometrial
cancer results from a common inherited genetic variant. Also it is plaus-
ible thatother factors, such as parity (nulliparous versusmulti), age at ﬁrst
pregnancy and use/length of use of hormones (HRT, OCP), may act as
confounders.
The range of criteria used to diagnose PCOS is well recognized as a
cause for the variation in morbidity associated with this syndrome.
This was evident in the studies used in our analysis but this is to some
degree understandable because these studies were targeted as risk
factors for cancer and were not speciﬁcally focused on PCOS.
However, unlike the two previous meta-analyses, we excluded data
from women with asymptomatic polycystic ovaries. Like the previous
meta-analyses, we included self-reported diagnoses of PCOS, and also
diagnoses based on unusual criteria (for example, one study was based
on Goldzieher’s criteria (Niwa et al., 2000)). Some studies predate the
accepted Consensus Guidelines (ESHRE/ASRM, 2004) and therefore
could be expected not to conform to these criteria (Escobedo et al.,
1991; Schildkraut et al., 1996; Anderson et al., 1997; Talamini et al.,
Figure 5 Funnel plot of studies of endometrial cancer in womenwith
PCOS compared with controls.
Figure 6 Funnel plot of studies of ovarian cancer in women with
PCOS compared with controls.
Figure7 Funnel plot of studiesof breast cancer inwomenwith PCOS
compared with controls.
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1997; Niwa et al., 2000), whilst one study did not specify the diagnostic
criteria (Iatrakis et al., 2006). Much of the diagnostic data were self-
reported and a diverse range of control cohorts were used (Talamini
et al., 1997; Niwa et al., 2000; Baron et al., 2001; Iatrakis et al., 2006).
Indeed where studies reported a high risk cancer when compared with
age-correctedestimatedpopulation incidence, this suggests potential se-
lection bias. Clearly, inclusion of these studies with possible selection
biases is a limitation of the present study.
The diversity of the included studies can be clearly seen from Table I.
The heterogeneity evident can be summarized as being due to variation
in PCOS phenotypes in different ethnicities, diagnostic criteria for PCOS
and cohort sizes. Tomitigate the effects of heterogeneity we have used a
random effects model where appropriate. The CIs for some of the
studies crossed zero meaning that no signiﬁcant risk could be deter-
mined, though in the case of endometrial cancer a signiﬁcant risk was
identiﬁed (see Table III). Additionally our meta-analysis was limited by
the small number of studies suitable for inclusion and their overall
quality. We used a comprehensive article and abstract screening
process and an extensive three-stage search technique was utilized to
maximize article recognition. Although publication bias could not be
ruledout (seeFigs 5–7), noneof the studies included in thismeta-analysis
wereof poorquality, as ratedusing theNOS formeasuringquality assess-
ment (Table II).
On the basis of the available evidence, it is reasonable to conclude that
there is an increased cancer risk, at least for endometrium, in women
with PCOS. However the other equally important conclusion to be
drawn from our systematic review is that the available evidence is far
from robust, so that variation in diagnostic criteria for PCOS, associated
risk factors (particularly obesity), and selection bias may have resulted in
anexaggerationof the increased risk.WomenwhohavePCOSshouldbe
made aware that the increased risk we report for endometrial cancer
must be judged in the context of the relatively low incidence in the
general population (Cancer Research UK, 2013).
The current uncertainty regarding cancer risk in PCOS is not likely
to be resolved by additional case–control studies, the design of which
allows limited scope for controlling for the effect of different con-
founding factors and interactions between them. It is imperative
that any association between PCOS and cancer is examined further
in the context of an appropriately powered prospective longitudinal
cohort study. The results of such a study will not only deﬁne the
risk more clearly, but could facilitate the development of screening
of subgroups at greatest risk. This is important because there may
be primary interventions, such as lifestyle changes (Birks et al.,
2012) and metformin treatment (Landman et al., 2009), that may miti-
gate this excess risk.
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